Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-20-099

Harmonization of Alzheimers Disease and Related Dementias (AD/ADRD) Genetic, Epidemiologic, and Clinical Data to Enhance Therapeutic Target Discovery (U24 Clinical Trial Not Allowed)

Closed on January 25, 2023.

Posted
January 23, 2020
Close date
January 25, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,835,050 in first-year total cost, median $6,835,050.

Most frequent study sections

  1. Special Emphasis Panel[ZAG1 ZIJ-P (O1)]1

Most frequent institutions

  1. VANDERBILT UNIVERSITY MEDICAL CENTER1
Competing awards under PAR-20-099 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium1U24AG074855-01CUCCARO, MICHAEL LHOHMAN, TIMOTHY JTOGA, ARTHUR WVANDERBILT UNIVERSITY MEDICAL CENTER, TN$6,835,050ZAG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-20-099: Harmonization of Alzheimers Disease and Related Dementias (AD/ADRD) Genetic, Epidemiologic, and Clinical Data to Enhance Therapeutic Target Discovery (U24 Clinical Trial Not Allowed) | ScienceDex | ConductScience